Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027211 | 0.86 | AOC3 (0.43) | KDM4EHSD17B10ALDH1A1LMNAHPGD | |
| SCHEMBL21262192 | 0.84 | KDM4E (0.45) | KDM4EHSD17B10ALDH1A1LMNAMTNR1A | |
| SCHEMBL7809964 | 0.82 | KDM4E (0.53) | KDM4EHSD17B10ALDH1A1LMNAALOX15 | |
| SCHEMBL8477532 | 0.81 | KDM4E (0.51) | KDM4EHSD17B10ALDH1A1LMNAALOX15 | |
| SCHEMBL23112391 | 0.81 | KDM4E (0.51) | KDM4EHSD17B10ALDH1A1LMNAALOX15 | |
| SCHEMBL11354980 | 0.79 | HPGD (0.54) | KDM4EHSD17B10ALDH1A1ALOX15MTNR1A | |
| SCHEMBL4714664 | 0.78 | KDM4E (0.58) | KDM4EHSD17B10ALDH1A1LMNAALOX15 | |
| SCHEMBL19380526 | 0.78 | KDM4E (0.49) | KDM4EHSD17B10ALDH1A1LMNAALOX15 | |
| SCHEMBL637323 | 0.76 | CTNNB1 (0.55) | KDM4EHSD17B10ALDH1A1LMNAALOX15 | |
| SCHEMBL9838523 | 0.74 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223834-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2020-07-16 | — | — | US | disclosed |
| US-10457672-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190055227-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-02-21 | — | — | US | disclosed |
| US-9951053-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951053-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-9533976-B2 | γ-diketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| WO-2014130869-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | SAMUMED, LLC (US) | 2014-08-28 | — | — | WO | disclosed |
| EP-1373257-B9 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1373257-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-28 | — | — | EP | disclosed |
| US-6949544-B2 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030087922-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223834-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | KDM4E 3701/4885HSD17B10 1006/4885ALDH1A1 1019/4885 |
| US-20190055227-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | KDM4E 3701/4885HSD17B10 1006/4885ALDH1A1 1019/4885 |
| US-20030087922-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | CDK2, LCK, CDK5 | KDM4E 1096/4885HSD17B10 4252/4885ALDH1A1 4705/4885 |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | KDM4E 3701/4885HSD17B10 1006/4885ALDH1A1 1019/4885 |
| US-10457672-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | KDM4E 3614/4885HSD17B10 932/4885ALDH1A1 1093/4885 |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | KDM4E 3701/4885HSD17B10 1006/4885ALDH1A1 1019/4885 |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | KDM4E 3652/4885HSD17B10 996/4885ALDH1A1 1024/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | KDM4E 3614/4885HSD17B10 932/4885ALDH1A1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.